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Endoscopy remission rate was very similar to the second his-
tological score (36 children). No significant contribution came 
from the application of immunohistochemistry.
The comparison between the first work and this extension 
reveals a higher percentage of MH reached by only activity 
examination then by the architectural and inflammatory score 
(68% vs 53%) and a very high concordance with endoscopy.
Thirty-one patients were re-biopsed between 12 and 24 
months after this therapy: among them 11 patients had disease 
relapse. Agreement between MH and follow up was found in 
18 patients for the first score and 21 patients for the activity 
score (respectively 58% and 67% of cases). Relapses were 
predicted in 6 cases by the first score and 5 cases by the sec-
ond; when the scores were summed, prediction was found in 
7 patients (64%).
Conclusions. In this work, we explored the contribution of 
pathology in the evaluation of MH as an endpoint of a Aza-
thioprine therapy in children affected by IBD.
At the beginning of this investigation, no MH definition exist-
ed in histopathology, and a good correlation with endoscopic 
MH was the goal of our investigation in MH.
Recent experiences converged to a simple MH based on ab-
sence of activity alone.
Our study follows this trend: when MH was defined just by the 
absence of activity in biopsies, correlation with clinical data and 
endoscopy was high. Moreover, when compared with follow 
up, about 2/3 of courses were predictable by MH.
MH based on evaluation of architectural changes and inflam-
matory infiltrate, tissue eosinophils was found less informative.
Prediction of relapse is probably the most interesting datum 
achievable by MH. The weak higher significance of the first 
score could indicate a contribution yet to be delineated from 
the whole evaluation of the architectural changes and inflam-
matory infiltrate in predicting relapse.
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Objectives. Necroptosis (NCP) is a form of programmed cell 
death characterized by the lysis of cellular elements and it in-
volves the formation of a necrosis-inducing complex consist-
ing of the receptor-interacting protein kinases 1 and 3 (RIPK1 
and RIPK3) and the mixed-lineage kinase domain-like protein 
(MLKL) (1). NCP is involved in promoting inflammation 
under pathological conditions and recent studies on NCP 
have shown that some cancer cells may show a preferential 
reduction in the expression of the key mediators of NCP, sug-
gesting that it may negatively regulate tumorigenesis. When 
NCP occurs in cancer cells, dispersed elements in the tumor 
microenvironment may contribute to cancer development by 
influencing local immune response, which can be assessed 
by the quantification of T cell infiltration in cancer. This can 
be done by using a reliable and reproducible method as the 
immunoscore (2), that may be applied also to hepatocellular 
carcinoma (HCC) (3). Aim of this study was to assess expres-
sion of RIPK1, RIPK3 and phosphorylated MLKL in cohort 
HCC patients and their correlation with T cell infiltration and 
clinical follow-up data.
Methods. RIPK1, RIPK3 and MLKL-p expressions were 
assessed by immunohistochemistry in 76 FFPE samples of 
resected HCC patients. Expression was evaluated on a 4-tired 
scale based on the percentage of positivity stain in tumor cells, 
where 0 indicates absent staining, 1+ indicates less than 5%, 2+ 
indicates positive staining between 6% to 50%, and 3+ indi-
cates positive staining >50%. Both overall and disease-free sur-
vival analyses were performed on the patients stratified by high 
and low expression of the necrosis-inducing complex. Specifi-
cally, patients showing 3+ staining in at least two genes of the 
necrosis-inducing complex were grouped separately from the 
other cases. Tumor and peritumoral infiltrating CD3 and CD8 
T assessment on fully digitized HCC sections and molecular 
quantification of RIPK1, RIPK3 and MLKL-p are in progress.
Results. RIPK1 showed 0+ in 18/76 cases; 1+ in 27/76 cases; 
2+ in 20/76 cases and 3+ in 11/76 with cytoplasmic localiza-
tion or in the membrane. RIPK3 immunoprofile resulted in 
13/76, 10/76, 11/76 and 42/76 positive cases for 0+,1+,2+ 
and 3+ respectively; with cytoplasmic localization. MLKL-p 
resulted in 35/76, 24/76, 13/76 and 4/76 positive cases respec-
tively 0+, 1+, 2+ and 3+; with cytoplasmic localization or in 
the membrane (Fig. 1). Both overall and disease-free survival 
analyses showed significant correlation between poor prog-
nosis and down-regulation of the necrosis-inducing complex, 
with log- rank test p-values 0.048 and 0.012, respectively.
Conclusions. Considering our preliminary data NCP occurs 
in a subset of HCC patients and it could represent an easy and 
reliable parameter for the evaluation of HCC immunogenic-
ity and for the evaluation of tumoral aggressiveness. These 
results will be compared to those obtained in larger cohorts 
from publicly available datasets (e.g. data from TCGA and 
ICGC consortia) to validate the role of NCP in the hepatocel-
lular carcinoma.
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Background. ExtraNodal Extension (ENE) of lymph node 
(LN) metastasis has recently asserted itself as a significant 
prognostic factor in colorectal cancer (CRC). The molecular 
background on the development of ENE phenotype has not 
been investigated, as yet.
Methods. A retrospective and consecutive series of 22 CRCs 
and their matched ENE- lymph node metastasis was enrolled 
(M/F=15/7; median age 70.2±13.7 years; grading G2=4, 
G3=18; staging IIIb=2, IIIc=14, IV=6; all Caucasians). Three 
different specimens per each case were obtained respectively 
from the formalin-fixed paraffin-embedded (FFPE) primary 
CRC, an ENE-negative LN metastasis and an ENE-positive 
one. DNA was extracted from 15 cases after neoplastic cell 
enrichment and, subsequently, it was profiled by the applica-
tion of an hotspot multigene mutational custom panel, includ-
ing 164 hotspot regions of AKT1, APC, BRAF, CTNNB1, 
KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN and TP53 
genes (Diatech Pharmacogenetics, Jesi, Italy) and run on a 
MassARRAY Dx Analyzer 4 (Agena Bioscience, Hamburg, 
Germany). Somatic mutations were corroborated by Sanger 
sequencing. The 66 selected specimens were analysed by im-
munohistochemistry for PDL-1 (clone 22C3; Dako, Glostrup, 
Denmark), CD4, CD8, CD68 and CD80. The percentage of 
cells showing a positive immunoreactivity was appraised in: I) 
core of CRC; II) invasive front of CRC; III) core of neoplastic 
cells in both the ENE-negative and ENE-positive LN metas-
tasis; IV) invasive front of the ENE-positive LN metastasis.
RESULTS: 14 out of 15 CRCs (93%) showed at least a driver 
mutation in the primary tumour. The most frequently mutated 
gene was TP53 (8 tumours), followed by APC (6), BRAF 
(4), KRAS (2), NRAS (2) and PIK3CA (2). In 11 out of 15 
CRCs (73%) the mutational profiling of the primary tumour 
was consistent with what obtained from the two matched 
metastatic LN (ENE-negative and ENE-positive). The mo-
lecular inconsistency of the last 4 cases could be referred to 
the intratumour heterogeneity in accordance with Literature. 
A significantly higher percentage of CD4, CD8 and CD68 
positive cells was observed at the invasive front of CRCs and 
their matched ENE-positive LN metastasis in contrast with 
what observed at the core of both CRCs and neoplastic cells in 
their matched ENE-negative and ENE-positive LN metastasis. 
A significantly higher CD80 percentage was solely observed 
at the invasive front of ENE. No significant difference of 
PDL-1 positive cell percentage was observed among the dif-
ferent specimens.
Conclusions. The neoplastic ability to infiltrate the LN cap-
sule reflects the aggressiveness of the primary tumour but, in 
our study, it seems there is no ENE specific molecular signa-
ture. However, the detection of a significantly higher percent-
age of CD4, CD8, CD68 and CD80 cells at the ENE invasive 
front might encourage further investigations on a possible 
application of immunotherapy in ENE-positive CRCs.
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Background. Accurate detection of Helicobacter pylori (HP) 
is essential for managing infected patients and for eradicating 
therapy. Since the discovery of HP, several diagnostic meth-
ods have been developed with the aim of accurately detecting 
of this bacterium. These tests include non invasive method-
serology, urea breath test, or stool antigen test and invasive 
methods, such as, culture, histological examination, and rapid 
urease test, which require upper gastrointestinal endoscopy 
to obtain gastric biopsy samples. Among these, histological 
examination is one of the most useful diagnostic tests for HP 
infection. Recently, it has been produced a new era of urease 
test (ultrarapid) enables a rapid diagnosis within 5 minutes 
during gastroscopy. We compare this test with histological 
and immunoistochemical (IHC) examination. For all biopsies 
we evaluate the histological quality after its utilisation.
Methods. We start with the observational prospectical mono-
centric study (PRIMUM) enrolling 42 patients >18 years in 
order to evaluate the efficacy of the ultrafast test (BioTest 
HD®). Criteria of exclusions were a suspicious of carcinoma 
and a previous utilisation of proton pump inhibitors, antibiot-
ics or colloidal bismuth by patients. The antral gastric biopies 
were immediately immersed in the liquid of the test com-
prehensive of blue of bromotimolo and urea (ph5.5). After 5 
minutes the gastroenterologists evaluated the results of test 
according a scale from 0 to 3. In the positive cases the colour 
of test changed from yellow (Fig. 1A) to blue (Fig. 1B). After 
this evaluation biopsies were fixed in formalin and sended to 
the routinely process. The pathologists evaluated the quality of 
specimen (antral and body biopsies), the inflamamtory lesions 
and the presence of HP infection both with Ematoxilin&Eosin 
and Giemsa stained slide and by immunoistochemistry (IHC).
Results: Between 42 cases 10 (23,8%) resulted positive to 
